这是临床首次报道逆转录病毒载体(RV)制备的Anti-BCMA CAR-T细胞联合自体干细胞移植(ASCT)治疗MM患者,证明了深圳细胞谷以RV制备的新型Anti-BCMA CAR-T细胞联合ASCT治疗难治性MM患者具有很好的疗效与安全性。目前Anti-BCMA CAR-T临床研...
这是临床首次报道逆转录病毒载体(RV)制备的Anti-BCMA CAR-T细胞联合自体干细胞移植(ASCT)治疗MM患者,证明了深圳细胞谷以RV制备的新型Anti-BCMA CAR-T细胞联合ASCT治疗难治性MM患者具有很好的疗效与安全性。目前Anti-BCMA CAR-T临床研究已入组5名MM患者,均取得了可观的疗效。 深圳细胞谷与华中科技大学深圳协和医院...
凭借李宗海博士及其团队在 CAR-T 细胞疗法领域多年的深厚积累,科济药业开发了全人抗 BCMA 自体 CAR-T 产品 CT053。经过基因修饰,CT053 可表达融合了具有高亲和力的全人源 BCMA 特异性单链片段(scFv)25C2 的 CAR,其免疫原性降低而安全性提高,兼具了良好的疗效和安全性,相继获得了美国 FDA 的“再生医学先进疗法...
BCMA已成为多发性骨髓瘤(MM)和其他血液恶性肿瘤(霍奇金淋巴瘤、非霍奇金淋巴瘤、胶质母细胞瘤等)的一个非常热门的免疫治疗靶点。目前,全球已有两款靶向人BCMA CAR-T细胞治疗产品上市,用于复发/难治性多发性骨髓瘤(r/r MM)患者,临床效果积极,总缓解率(ORR)超过70%,部分患者可长期维持深度缓解。
Based on this, we hypothesize that CELMoDs can improve anti-BCMA CAR-T function and ultimately clinical outcomes. Methods: We evaluated the impact of novel CELMoDs Iberdomide and Mezigdomide on the persistence, proliferation, and activation of healthy donor derived Anti-BCMA CAR-T cells. ...
The response rate and the depth of responses induced by anti-BCMA CAR T cells are impressive; however, the majority of patients eventually relapse. Understanding the underlying mechanisms of response and resistance in treated MM patients will be critical to the rational development of this therapy....
B cell maturation antigen (BCMA) is a target for various immunotherapies and a biomarker for tumor load in multiple myeloma (MM). We report a case of irreversible BCMA loss in a patient with MM who was enrolled in the KarMMa trial (NCT03361748) and progressed after anti-BCMA CAR T cel...
(CAR) T cells (CART-BCMA) are a promisingtreatment for relapsed/refractory multiple myeloma (r/rMM). Weevaluated the safety and feasibility of bridging radiation (RT) insubjects treated on a phase I trial of CART-BCMA.Experimental Design: Twenty-f i ve r/rMM subjects were treatedin three...
Chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of neurological autoimmune diseases is promising, but CAR T cell kinetics and immune alterations after treatment are poorly understood. Here, we performed single-cell multi-omics sequencing of paired cerebrospinal fluid (CSF) and ...
19 global pandemic continues, the decision of whether to proceed with CAR T cell therapy will require extensive discussion weighing the potential risks and benefits of therapy. This case suggests that it is possible to successfully complete anti-BCMA CAR T cell therapy after recovery from COVID-...